LP-003 injection for chronic rhinosinusitis with nasal polyps
Tests LP-003 injection against placebo in adults with chronic rhinosinusitis with nasal polyps.
Key facts
- Who runs it
- Longbio Pharma
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 150 people, planned
- Started
- 20 Jan 2026
- Expected to end
- 30 Sept 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- LP-003 Injection
- Placebo of LP-003
- Record updated
- 6 February 2026
Who can take part
The trial is looking for adults with chronic rhinosinusitis with nasal polyps in both sides of the nose. Their symptoms must continue despite earlier treatment. The trial tests LP-003 Injection against a placebo.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Nasal polyps on both sides. Nasal Polyp Score (NPS) ≥ 5 points, with at least ≥ 2 points in each side of the nose. Moderate to severe nasal congestion (NCS of 2 or 3 points, weekly mean ≥ 2 points). Nasal congestion plus one other symptom for ≥ 4 weeks.
- Earlier treatment
- Polyps still present after systemic corticosteroids (such as steroid tablets) within 2 years, or steroids cannot be used or are not tolerated, and/or polyp surgery within 6 months. Stable nose steroid spray dose for at least 4 weeks. At least 80% use of mometasone furoate nasal spray during the run-in period, for at least 14 days.
- Main reasons for not taking part
- Other nose diseases, or a current upper airway infection or serious infection
- Weak immune system or past serious opportunistic infections, or a parasite infection
- Recent systemic steroids, monoclonal antibodies (such as Dupilumab, Omalizumab) within 10 weeks, or immunosuppressant drugs
- Asthma with FEV1 ≤ 50% of the predicted value
- Pregnant or breastfeeding women
Show the full registry criteria (21)Hide the full registry criteria
Who can take part
- Capable of understanding the study and voluntarily signing the Informed Consent Form (ICF)
- Aged 18 to 75 years (inclusive) at the time of signing the ICF, regardless of gender
- Diagnosis of bilateral chronic rhinosinusitis with nasal polyps (CRSwNP)
- Persistence of the following symptoms for ≥ 4 weeks prior to the screening/run-in period:; Nasal congestion; Any one of the other symptoms: mucoid or mucopurulent nasal discharge, head and facial distension/pain, hyposmia or anosmia
- Nasal Polyp Score (NPS) ≥ 5 points, with each nasal cavity scoring at least ≥ 2 points during the screening/run-in period and prior to randomization
- Participants report moderate to severe nasal congestion during the screening/run-in period and prior to randomization:; Nasal Congestion Score (NCS) of 2 or 3 points at the screening/run-in period (Visit 1, V1); Mean weekly NCS ≥ 2 points prior to randomization
- With bilateral CRSwNP despite prior treatment with systemic corticosteroids (SCS) such as oral corticosteroids (OCS) within 2 years prior to screening; and/or has contraindications to SCS treatment or is intolerant to SCS; and/or has undergone nasal polypectomy within 6 months prior to screening, with persistent bilateral CRSwNP
- Has been on a stable dosage of intranasal corticosteroids (INCS) for at least 4 weeks prior to screening
- Demonstrates ≥80% adherence to mometasone furoate nasal spray (MFNS) administration during the run-in period (with a minimum of 14 days of use)
Who cannot take part
- Concurrent other nasal diseases or nasal symptoms
- Severe infection requiring intravenous antibiotics and/or hospitalization within 4 weeks prior to randomization that has not yet resolved, or active infection requiring oral antibiotics within 2 weeks prior to randomization that has not yet resolved; the investigator assesses that enrollment of the participant may pose uncontrollable risks
- Concurrent active parasitic infection (e.g., helminths) or suspected parasitic infection
- Current or prior receipt of the following treatments:; Use of traditional Chinese medicine (TCM) or proprietary Chinese medicines for chronic rhinosinusitis within 1 week prior to screening; Use of medium- or short-acting systemic corticosteroids (SCS) within 4 weeks prior to randomization, or long-acting SCS within 6 weeks prior to randomization; Receipt of any systemic monoclonal antibody therapy [e.g., Stapokibart, Dupilumab, Mepolizumab, Omalizumab, Tezepelumab, etc.] within 10 weeks prior to randomization or within 5 half-lives (whichever is longer); Use of systemic immunosuppressants within 4 weeks prior to randomization or within 5 half-lives (whichever is longer); Initiation of leukotriene receptor antagonist (LTRA) therapy within 4 weeks prior to randomization (participants who have been receiving stable-dose LTRA therapy for at least 4 weeks prior to randomization are eligible for enrollment)
- For participants with concurrent asthma, the forced expiratory volume in 1 second (FEV1) as a percentage of predicted value ≤ 50% during the screening/run-in period
- Known allergy or intolerance to any component of the investigational product and/or mometasone furoate nasal spray
- Acute upper respiratory tract infection at screening, which the investigator assesses may affect nasal symptom scoring
- Known or suspected history of immunosuppression, including a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis); or participants with a history of such infections that have resolved but are assessed by the investigator as likely to recur frequently
- Any severe or unstable disease that the investigator believes may affect the participant's safety during the study and/or hinder the participant from completing the study
- Has any severe or unstable disease that, in the investigator's judgment, may affect the safety of the trial participant during the study and/or preclude the participant from completing the study, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, autoimmune, hematological, or psychiatric disorders
- Any other conditions that the investigator deems inappropriate for the participant to participate in the study
- Pregnant or lactating females
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Chronic rhinosinusitis with nasal polyps
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. Its primary objective is to explore and preliminarily evaluate the efficacy and safety of LP-003 Injection in the treatment of participants with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to investigate its pharmacokinetic (PK), pharmacodynamic (PD) profiles, and immunogenicity.
The 3 groups in the trial
- LP-003 300 mg groupTreatment being tested
Participants will receive subcutaneous injection of LP-003 Injection at a dose of 300 mg once every 12 weeks.
Treatment: LP-003 Injection
- LP-003 450 mg groupTreatment being tested
Participants will receive subcutaneous injection of LP-003 Injection at a dose of 450 mg once every 12 weeks.
Treatment: LP-003 Injection
- PlaceboPlacebo, for comparison
Participants will receive subcutaneous injection of placebo Injection once every 12 weeks.
Treatment: Placebo of LP-003
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase Ⅱ Clinical Trial to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Plain-language title
- LP-003 injection for chronic rhinosinusitis with nasal polypsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07313917, who can take part
- Record updated
- 6 February 2026